Evidence map›Paper›PMID 35152664›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2022

[Clinical application of serum Golgi protein 73 in patients with chronic liver diseases].

Y N Liu, M J Yao, S J Zheng, X M Chen, X Y Liu, P Hu, Q S Ou, X G Dou, H S Chen, Z P Duan and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. [Meta-analysis of the efficacy of the Fuzheng Huayu formula in the treatment of hepatitis B-associated liver fibrosis or cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Y N LiuDepartment of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China.
M J YaoDepartment of Anatomy and Embryology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
S J ZhengLiver Diseases Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China.
X M ChenDepartment of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China.
X Y LiuDepartment of Clinical Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
P HuDepartment of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Q S OuDepartment of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
X G DouDepartment of Infectious Diseases, Shengjing Hospital, China Medical University, Shenyang 110022, China.
H S ChenHepatology Institute, Peking University People's Hospital, Beijing 100044, China.
Z P DuanLiver Diseases Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China.
J L HouGuangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Y M NanDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
Z L GaoDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
X Y XuDepartment of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
H ZhuangDepartment of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China.
F M LuDepartment of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
Peking University · CNChongqing Medical University · CNFirst Affiliated Hospital of Fujian Medical University · CNHebei Medical University · CNNanfang Hospital · CNPeking University People's Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Golgi protein 73 (GP73) is a transmembrane protein on the Golgi apparatus and can be cut and released into the blood. In recent years, an increasing number of clinical studies have shown that the elevated serum GP73 level is closely related to liver diseases. And thus GP73 is expected to be used as a new serum marker for assessing progress of chronic liver diseases. Herein, the clinical application of serum GP73 in chronic hepatitis, liver fibrosis, liver cirrhosis and hepatocellular carcinoma with different etiologies was reviewed based on available literatures; and a research outlook in this field is made.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkersGolgi ApparatusHumansLiver CirrhosisBiomarkersGolgi proteinLiver cirrhosisLiver diseasesLiver fibrosisLiver inflammationSerum biomarker

Identifiers

PMID35152664
PMCPMC12769231
OpenAlexW4212977077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.